Subscribe To
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023

-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures- -Clinical improvement consistently seen across key measures at week 12, mMCS response of 45.7% and endoscopic improvement of 25.7%- -MORF-057 well tolerated with no safety signals observed- -PK/PD confirm results seen in healthy volunteer studies, with median RO >99% […] The post Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in...
Read More
Posted: Sep 22 2023, 21:30
Author Name: forextv
Views: 091084